Department of Medicine, University of Alabama at Birmingham, AL 35294, USA.
J Infect Dis. 2011 Jun 1;203(11):1534-41. doi: 10.1093/infdis/jir138.
Traditionally, vaccines have been utilized to generate immune responses to a pathogen in a naive population. In the setting of congenital cytomegalovirus (CMV) infection, a vaccine that, when administered to women already infected with CMV, could boost the mother's immunity to CMV would most likely be beneficial in diminishing in utero transmission of CMV. However, the ability to boost an immune response in a population of individuals seropositive for a pathogen of interest is not well studied. This study examines the ability of a recombinant CMV glycoprotein B vaccine with MF59 adjuvant to boost both antibody (neutralizing and enzyme-linked immunosorbent assay end point dilution titer) and CD4+ T-cell responses in previously CMV-seropositive women by way of natural infection. These data suggest that this vaccine is capable of boosting immunity in a population of CMV-infected women and warrants additional evaluation to determine whether these boosted responses may prevent mother to child transmission of CMV.
传统上，疫苗被用于在未感染人群中产生针对病原体的免疫反应。在先天性巨细胞病毒（CMV）感染的情况下，如果有一种疫苗可以在已经感染 CMV 的女性中使用，增强母亲对 CMV 的免疫力，那么这种疫苗很可能有助于减少 CMV 的宫内传播。然而，在针对感兴趣的病原体呈血清阳性的人群中增强免疫反应的能力尚未得到很好的研究。本研究通过自然感染，检查了含有 MF59 佐剂的重组 CMV 糖蛋白 B 疫苗增强先前 CMV 血清阳性妇女的抗体（中和和酶联免疫吸附试验终点稀释滴度）和 CD4+T 细胞反应的能力。这些数据表明，这种疫苗能够增强 CMV 感染妇女的免疫力，值得进一步评估，以确定这些增强的反应是否可以防止 CMV 的母婴传播。
